# Blade Brown Takes Investor and Partner Role at UK Medical Cannabis Clinic Mamedica > Blade Brown has joined Mamedica as an investor and partner, backing the UK medical cannabis clinic after its £4.5 million funding round and £21.5 million in annualised sales. - Published: 2026-10-31T16:18:42+00:00 - Section: Leadership - Author: News Desk - URL: https://newsforagent.com/news/2026-10-31/blade-brown-mamedica-investor-partner - Source: [Yahoo](https://www.yahoo.com/entertainment/music/articles/exclusive-blade-brown-moves-medical-152130689.html) ## Key takeaways - Blade Brown joined Mamedica as an investor and partner, backing the UK medical cannabis company. - Mamedica secured £4.5 million in funding led by Casa Verde in September 2025. - Mamedica's annualised sales reached £21.5 million in 2025 and its patient base surpassed 15,000. Blade Brown has joined Mamedica as an investor and partner, backing the UK medical cannabis company as it grows in the country's regulated medical cannabis market. Brown disclosed the move to Complex UK, in a report published by [Yahoo](https://www.yahoo.com/entertainment/music/articles/exclusive-blade-brown-moves-medical-152130689.html). Mamedica secured £4.5 million in funding led by Casa Verde in September 2025, and its annualised sales reached £21.5 million in 2025. ## Brown's Move Into Medical Cannabis Brown said the investment marks a step in expanding beyond music into new industries. He said he had followed the UK medical cannabis sector since it became legal in 2018 and had spent three to four years looking for the right opportunity to get involved. "Mamedica stood out to me because of what they were doing and the vision they had for the industry, which aligned with what I wanted to be part of," he said. Brown said there is still a significant lack of awareness around the legal medical cannabis sector in the UK and that more people should understand the treatment options available. He described the industry as still in its early stages, with potential for growth. Jon Robson, CEO and founder of Mamedica, said Brown understands both the cultural history surrounding cannabis and the importance of building its legal, regulated future. "Having him join Mamedica as an investor and partner comes at an important point in our growth, as we reach more patients and continue to build the business," Robson said. Robson said Brown's backing supports the company's ambition to make specialist treatment more accessible across the UK. ## Mamedica's Funding and Patient Base [Mamedica](https://akta.pro/company-profiles/0000j9q/mamedica) closed a £4.5 million funding round in September 2025 led by US-based cannabis-focused investor [Casa Verde Capital](https://akta.pro/company-profiles/0000c2u/casa-verde-capital), according to akta.pro [company records](https://akta.pro/company-data). The same records list a 2025-09 seed round of $6.1 million led by Casa Verde Capital. The records state the company is trusted by 15,000+ patients, and that it stated strategic intent to double patient numbers annually and expand operations across Europe as the UK cannabis industry approaches £1 billion in sales by 2028. The records also note a #8 ranking in The Sunday Times 100 2026. ## Leadership Moves Across Healthcare THL Partners appointed Bruce Robertson as Managing Director on its Healthcare investment team on October 19, 2026, joining from H.I.G. Capital, [citybiz](https://www.citybiz.co/article/920573/thl-partners-appoints-bruce-robertson-managing-director-on-healthcare-investment-team/) reported. Davion Healthcare Plc appointed Glenn Williams as CEO and Jeremy North as COO, [Stock Titan](https://www.stocktitan.net/news/DAVI/davion-healthcare-plc-confirms-expected-nasdaq-trading-date-and-dmy6bimajj3g.html) reported on October 20, 2026. Sciety appointed Recipharm co-founder Thomas Eldered as Senior Advisor, [news.cision.com](https://news.cision.com/sciety/r/sciety-welcomes-recipharm-co-founder-thomas-eldered-as-senior-advisor,c4412225) reported on October 21, 2026. ## Davion's Nasdaq Trading Date Davion Healthcare Plc expects its ordinary shares to start trading on Nasdaq on October 22, 2026, under ticker DAVI, according to Stock Titan. The company also launched a £30 million bond to fund acquisitions and established an Operational Directorate to lead commercialisation and growth. ## Companies in this story - [Mamedica company profile](https://akta.pro/company-profiles/0000j9q/mamedica) · website: https://www.mamedica.com - [Casa Verde Capital company profile](https://akta.pro/company-profiles/0000c2u/casa-verde-capital) · website: http://www.casaverdecapital.com --- News for Agent · https://newsforagent.com/llms.txt